ORAL PRESENTATIONS | MODERATORS

**Sunday, September 21**
Educational Session 107: Targeted Radionuclide Therapy
4:15 – 5:45 pm
Room 252
Systemic Radiopharmaceutical Update on Radioimmunotherapy: New Trends and Data
Roger Macklis, MD

**Monday, September 22**
Poster Discussion 1: Lung Cancer I
10:15 – 11:45 am
Room 156
PET and Locally Advanced Lung Cancer
Gregory Videtic, MD, and Andrew Hope, MD, Co-Moderators

**Monday, September 22**
Educational Session 211: Challenging Cases in the Management of Newly Diagnosed and Recurrent Prostate Cancer
10:15 – 11:45 am
Room 210
Eric Klein, MD, Anthony D’Amico, MD, PhD, W. Ribert Lee, MD, Chris Parker, MD, James W. Denham, MD, MB, Co-Moderators

**Tuesday, September 23**
Scientific Session I: Lung I SBRT
11 am – 12:30 pm
Room 258
A comparison of stereotactic body radiation (SBRT) fractionation schedules for Stage I non-small cell lung cancer (NSCLC): the Cleveland Clinic experience.
Stephans K, Djemil T, Gajdos S, Reddy C, Videtic G

Tuesday, September 23
Scientific Session M: CNS II
1:45 – 3:15 pm
Room 252
Results of the Phase III ENRICH (RT-016) study of efaproxiral administered concurrent with whole brain radiation therapy (WBRT) in women with brain metastases from breast cancer.
Suh J, Stea B, Tankel K, Marsiglia H, Belkacemi Y, Gomez H, Falcone-Lizaraso S, May J, Saunders M.

Tuesday, September 23
Scientific Session M: Outcomes/Quality of Life
1:45 – 3:15 pm
Room 156
Functional interference clusters in cancer patients with bone metastases: an analysis of RTOG 9714.

Tuesday, September 23
Joint RRS/ASTRO Mini-Symposium 6: DNA Damage and Repair II
2:30 – 4:40 pm
Room 203
Role of proteasome-mediated degradation of Cyclin E in radiation sensitization.
Kathy Held, PhD, and Alex Almasan PhD, Co-Moderators

(continued on back)
POSTERS

Stereotactic spine radiosurgery (SRS) for pain and tumor control in patients with spinal metastases from renal cell carcinoma: a prospective study.
Angelov L, Chao S, Heng DY, Neyman A, Djemil T, Kolar M, Suh J.

SUVs from staging FDG-PET do not predict treatment outcomes for early stage NSCLC treated with SBRT.
Burdick MJ, Stephens KL, Reddy CA, Djemil T, Videtic GMM

New classification scheme to predict survival in patients with brain metastases from non-small cell lung cancer treated with upfront stereotactic radiosurgery.

Biochemical relapse-free survival in patients with high-risk prostate cancer treated with external beam radiotherapy, permanent seed implant monotherapy, or radical prostatectomy.

Accuracy and consistency in the identification of a novel non-migrating fiducial marker in CT images.
Djemil T, Mahadevan A, Schifter D, Macklis R, Corn B, Neustadter D.

Non-gaussian nature of prostate motion using real-time tracking and its impact on treatment margins.
Khan MK, Mahadevan A, Chen Q

The role of adjuvant radiation therapy in the treatment of spinal myxopapillary ependymomas.
Kobayashi T, Suh J, Benzel E, Reddy C, Chao S.

Gamma knife radiosurgery for single brain stem metastases: the Cleveland Clinic experience.

Histologic confirmation of SBRT of moving targets using respiratory gated radiation delivery.

Treatment outcomes for patients with low Karnofsky performance status at presentation with glioblastoma multiforme at a tertiary care institution.

Outcomes of patients with acoustic neuromas treated with gamma knife radiosurgery.

Accuracy of prostate rotation measurement based on 3 implanted fiducial markers.
Neustadter D, Djemil T, Mahadevan A, Schifter D, Macklis R, Corn B

Survival and prognostic factors for patients diagnosed with central nervous system radiation changes by pathology specimen: a retrospective analysis.
Peterson CR, Suh JH, Angelov L, Reddy C, Chao S.

Target positioning accuracy of a novel technology for target localization in radiation therapy.
Schifter D, Djemil T, Corn B, Mahadevan A, Lichtman R, Macklis R.

Aggressive treatment is appropriate for elderly (70 years and older) patients with glioblastoma multiforme: a retrospective review of 206 cases.

A comparison of biochemical relapse-free survival and initiation of salvage therapy in patients with intermediate-risk prostate cancer treated with open radical prostatectomy, laparoscopic radical prostatectomy, external beam radiotherapy, or permanent seed implantation.

ASTRO/RRS
Presidential Poster Session and Reception
Exhibit Hall A/B
Tuesday, September 23
5:00 – 6:30 pm